-
1
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
-
(2004)
N Engl J Med
, vol.351
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.3
Lara, Jr.P.N.4
Jones, J.A.5
Taplin, M.E.6
Burch, P.A.7
Berry, D.8
Moinpour, C.9
Kohli, M.10
Benson, M.C.11
Small, E.J.12
Raghavan, D.13
Crawford, E.D.14
-
2
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Tannock IF, de WR, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
-
(2004)
N Engl J Med
, vol.351
, pp. 1502-1512
-
-
Tannock, I.F.1
De, W.R.2
Berry, W.R.3
Horti, J.4
Pluzanska, A.5
Chi, K.N.6
Oudard, S.7
Theodore, C.8
James, N.D.9
Turesson, I.10
Rosenthal, M.A.11
Eisenberger, M.A.12
-
3
-
-
70349952400
-
Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
-
Mellado B, Font A, Alcaraz A, Aparicio LA, Veiga FJ, Areal J, Gallardo E, Hannaoui N, Lorenzo JR, Sousa A, Fernandez PL, Gascon P,. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer 2009; 101: 1248-1252.
-
(2009)
Br J Cancer
, vol.101
, pp. 1248-1252
-
-
Mellado, B.1
Font, A.2
Alcaraz, A.3
Aparicio, L.A.4
Veiga, F.J.5
Areal, J.6
Gallardo, E.7
Hannaoui, N.8
Lorenzo, J.R.9
Sousa, A.10
Fernandez, P.L.11
Gascon, P.12
-
4
-
-
38849155715
-
Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel
-
Domingo-Domenech J, Fernandez PL, Filella X, Martinez-Fernandez A, Molina R, Fernandez E, Alcaraz A, Codony J, Gascon P, Mellado B,. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol 2008; 19: 269-275.
-
(2008)
Ann Oncol
, vol.19
, pp. 269-275
-
-
Domingo-Domenech, J.1
Fernandez, P.L.2
Filella, X.3
Martinez-Fernandez, A.4
Molina, R.5
Fernandez, E.6
Alcaraz, A.7
Codony, J.8
Gascon, P.9
Mellado, B.10
-
5
-
-
33749336430
-
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity
-
Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campas C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B,. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 2006; 12: 5578-5586.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5578-5586
-
-
Domingo-Domenech, J.1
Oliva, C.2
Rovira, A.3
Codony-Servat, J.4
Bosch, M.5
Filella, X.6
Montagut, C.7
Tapia, M.8
Campas, C.9
Dang, L.10
Rolfe, M.11
Ross, J.S.12
Gascon, P.13
Albanell, J.14
Mellado, B.15
-
6
-
-
70350225568
-
Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling
-
Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Kaplan W, Breit SN, Sutherland RL, Henshall SM, Horvath LG,. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res 2009; 69: 7696-7703.
-
(2009)
Cancer Res
, vol.69
, pp. 7696-7703
-
-
Zhao, L.1
Lee, B.Y.2
Brown, D.A.3
Molloy, M.P.4
Marx, G.M.5
Pavlakis, N.6
Boyer, M.J.7
Stockler, M.R.8
Kaplan, W.9
Breit, S.N.10
Sutherland, R.L.11
Henshall, S.M.12
Horvath, L.G.13
-
7
-
-
25444514064
-
Blockage of NF-kappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells
-
Zerbini LF, Wang Y, Correa RG, Cho JY, Libermann TA,. Blockage of NF-kappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells. Cell Cycle 2005; 4: 1247-1253.
-
(2005)
Cell Cycle
, vol.4
, pp. 1247-1253
-
-
Zerbini, L.F.1
Wang, Y.2
Correa, R.G.3
Cho, J.Y.4
Libermann, T.A.5
-
8
-
-
69749117003
-
New insights into the role of interleukin-6 in human prostate cancer
-
Culig Z,. New insights into the role of interleukin-6 in human prostate cancer. J Urol 2009; 182: 1255-1256.
-
(2009)
J Urol
, vol.182
, pp. 1255-1256
-
-
Culig, Z.1
-
9
-
-
34247849312
-
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1
-
Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA, Culig Z,. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 2007; 26: 2822-2832.
-
(2007)
Oncogene
, vol.26
, pp. 2822-2832
-
-
Cavarretta, I.T.1
Neuwirt, H.2
Untergasser, G.3
Moser, P.L.4
Zaki, M.H.5
Steiner, H.6
Rumpold, H.7
Fuchs, D.8
Hobisch, A.9
Nemeth, J.A.10
Culig, Z.11
-
10
-
-
46749085910
-
Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma
-
Cavarretta IT, Neuwirt H, Zaki MH, Steiner H, Hobisch A, Nemeth JA, Culig Z,. Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Adv Exp Med Biol 2008; 617: 547-555.
-
(2008)
Adv Exp Med Biol
, vol.617
, pp. 547-555
-
-
Cavarretta, I.T.1
Neuwirt, H.2
Zaki, M.H.3
Steiner, H.4
Hobisch, A.5
Nemeth, J.A.6
Culig, Z.7
-
11
-
-
33845405558
-
Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328
-
Steiner H, Cavarretta IT, Moser PL, Berger AP, Bektic J, Dietrich H, Zaki MH, Nakada M, Hobisch A, Nemeth JA, Culig Z,. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate 2006; 66: 1744-1752.
-
(2006)
Prostate
, vol.66
, pp. 1744-1752
-
-
Steiner, H.1
Cavarretta, I.T.2
Moser, P.L.3
Berger, A.P.4
Bektic, J.5
Dietrich, H.6
Zaki, M.H.7
Nakada, M.8
Hobisch, A.9
Nemeth, J.A.10
Culig, Z.11
-
12
-
-
3242798367
-
NF-kappaB activation in human prostate cancer: Important mediator or epiphenomenon?
-
Suh J, Rabson AB,. NF-kappaB activation in human prostate cancer: Important mediator or epiphenomenon? J Cell Biochem 2004; 91: 100-117.
-
(2004)
J Cell Biochem
, vol.91
, pp. 100-117
-
-
Suh, J.1
Rabson, A.B.2
-
13
-
-
27944434722
-
Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse
-
Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, Alcover J, Campo E, Gascon P, Rovira A, Ross JS, Fernandez PL, Albanell J,. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 2005; 93: 1285-1294.
-
(2005)
Br J Cancer
, vol.93
, pp. 1285-1294
-
-
Domingo-Domenech, J.1
Mellado, B.2
Ferrer, B.3
Truan, D.4
Codony-Servat, J.5
Sauleda, S.6
Alcover, J.7
Campo, E.8
Gascon, P.9
Rovira, A.10
Ross, J.S.11
Fernandez, P.L.12
Albanell, J.13
-
14
-
-
51049109691
-
The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells
-
Zemskova M, Sahakian E, Bashkirova S, Lilly M,. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem 2008; 283: 20635-20644.
-
(2008)
J Biol Chem
, vol.283
, pp. 20635-20644
-
-
Zemskova, M.1
Sahakian, E.2
Bashkirova, S.3
Lilly, M.4
-
15
-
-
80053469996
-
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
-
O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, Rani S, O'Driscoll L, Fitzpatrick JM, Watson RW,. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer 2011; 10: 126.
-
(2011)
Mol Cancer
, vol.10
, pp. 126
-
-
O'Neill, A.J.1
Prencipe, M.2
Dowling, C.3
Fan, Y.4
Mulrane, L.5
Gallagher, W.M.6
O'Connor, D.7
O'Connor, R.8
Devery, A.9
Corcoran, C.10
Rani, S.11
O'Driscoll, L.12
Fitzpatrick, J.M.13
Watson, R.W.14
-
16
-
-
84856930016
-
Identification of docetaxel resistance genes in castration-resistant prostate cancer
-
Marin-Aguilera M, Codony-Servat J, Kalko SG, Fernandez PL, Bermudo R, Buxo E, Ribal MJ, Gascon P, Mellado B,. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther 2012; 11: 329-339.
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 329-339
-
-
Marin-Aguilera, M.1
Codony-Servat, J.2
Kalko, S.G.3
Fernandez, P.L.4
Bermudo, R.5
Buxo, E.6
Ribal, M.J.7
Gascon, P.8
Mellado, B.9
-
17
-
-
33745298519
-
Nuclear factor-kappaB in cancer development and progression
-
Karin M,. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436.
-
(2006)
Nature
, vol.441
, pp. 431-436
-
-
Karin, M.1
-
18
-
-
0038036872
-
Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer
-
Zerbini LF, Wang Y, Cho JY, Libermann TA,. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 2003; 63: 2206-2215.
-
(2003)
Cancer Res
, vol.63
, pp. 2206-2215
-
-
Zerbini, L.F.1
Wang, Y.2
Cho, J.Y.3
Libermann, T.A.4
-
19
-
-
65549130575
-
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor
-
Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, Moser PL, Fuchs D, Hobisch A, Culig Z,. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 2009; 16: 155-169.
-
(2009)
Endocr Relat Cancer
, vol.16
, pp. 155-169
-
-
Malinowska, K.1
Neuwirt, H.2
Cavarretta, I.T.3
Bektic, J.4
Steiner, H.5
Dietrich, H.6
Moser, P.L.7
Fuchs, D.8
Hobisch, A.9
Culig, Z.10
-
20
-
-
68049117221
-
Interleukin-6 regulates androgen synthesis in prostate cancer cells
-
Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, Evans CP, Gao AC,. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 2009; 15: 4815-4822.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4815-4822
-
-
Chun, J.Y.1
Nadiminty, N.2
Dutt, S.3
Lou, W.4
Yang, J.C.5
Kung, H.J.6
Evans, C.P.7
Gao, A.C.8
-
21
-
-
0032747375
-
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
-
Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G,. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3461-3467
-
-
Bubley, G.J.1
Carducci, M.2
Dahut, W.3
Dawson, N.4
Daliani, D.5
Eisenberger, M.6
Figg, W.D.7
Freidlin, B.8
Halabi, S.9
Hudes, G.10
Hussain, M.11
Kaplan, R.12
Myers, C.13
Oh, W.14
Petrylak, D.P.15
Reed, E.16
Roth, B.17
Sartor, O.18
Scher, H.19
Simons, J.20
Sinibaldi, V.21
Small, E.J.22
Smith, M.R.23
Trump, D.L.24
Wilding, G.25
more..
-
22
-
-
24044482568
-
Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis
-
Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D,. Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 2005; 44: 51-59.
-
(2005)
Mol Carcinog
, vol.44
, pp. 51-59
-
-
Venkatraman, M.1
Anto, R.J.2
Nair, A.3
Varghese, M.4
Karunagaran, D.5
-
23
-
-
73849090217
-
IKK/NF-kappaB and STAT3 pathways: Central signalling hubs in inflammation-mediated tumour promotion and metastasis
-
Bollrath J, Greten FR,. IKK/NF-kappaB and STAT3 pathways: Central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 2009; 10: 1314-1319.
-
(2009)
EMBO Rep
, vol.10
, pp. 1314-1319
-
-
Bollrath, J.1
Greten, F.R.2
-
24
-
-
68849108869
-
Inflammation and cancer: How friendly is the relationship for cancer patients?
-
Aggarwal BB, Gehlot P,. Inflammation and cancer: How friendly is the relationship for cancer patients? Curr Opin Pharmacol 2009; 9: 351-369.
-
(2009)
Curr Opin Pharmacol
, vol.9
, pp. 351-369
-
-
Aggarwal, B.B.1
Gehlot, P.2
-
25
-
-
72249093615
-
Tumor self-seeding by circulating cancer cells
-
Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massague J,. Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315-1326.
-
(2009)
Cell
, vol.139
, pp. 1315-1326
-
-
Kim, M.Y.1
Oskarsson, T.2
Acharyya, S.3
Nguyen, D.X.4
Zhang, X.H.5
Norton, L.6
Massague, J.7
-
26
-
-
2942627100
-
Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells
-
Pu YS, Hour TC, Chuang SE, Cheng AL, Lai MK, Kuo ML,. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 2004; 60: 120-129.
-
(2004)
Prostate
, vol.60
, pp. 120-129
-
-
Pu, Y.S.1
Hour, T.C.2
Chuang, S.E.3
Cheng, A.L.4
Lai, M.K.5
Kuo, M.L.6
-
27
-
-
76149103234
-
The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells
-
Morrissey C, Lai JS, Brown LG, Wang YC, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E, Nelson PS, Vessella RL,. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate 2010; 70: 412-424.
-
(2010)
Prostate
, vol.70
, pp. 412-424
-
-
Morrissey, C.1
Lai, J.S.2
Brown, L.G.3
Wang, Y.C.4
Roudier, M.P.5
Coleman, I.M.6
Gulati, R.7
Vakar-Lopez, F.8
True, L.D.9
Corey, E.10
Nelson, P.S.11
Vessella, R.L.12
-
28
-
-
66449085018
-
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2
-
Feng S, Tang Q, Sun M, Chun JY, Evans CP, Gao AC,. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther 2009; 8: 665-671.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 665-671
-
-
Feng, S.1
Tang, Q.2
Sun, M.3
Chun, J.Y.4
Evans, C.P.5
Gao, A.C.6
-
29
-
-
77449146168
-
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells
-
Santer FR, Malinowska K, Culig Z, Cavarretta IT,. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer 2010; 17: 241-253.
-
(2010)
Endocr Relat Cancer
, vol.17
, pp. 241-253
-
-
Santer, F.R.1
Malinowska, K.2
Culig, Z.3
Cavarretta, I.T.4
-
30
-
-
0028880675
-
Endogenous interleukin 6 is a resistance factor for cis- diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines
-
Borsellino N, Belldegrun A, Bonavida B,. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995; 55: 4633-4639.
-
(1995)
Cancer Res
, vol.55
, pp. 4633-4639
-
-
Borsellino, N.1
Belldegrun, A.2
Bonavida, B.3
-
31
-
-
23044498269
-
Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells
-
Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH,. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005; 65: 6934-6942.
-
(2005)
Cancer Res
, vol.65
, pp. 6934-6942
-
-
Li, Y.1
Ahmed, F.2
Ali, S.3
Philip, P.A.4
Kucuk, O.5
Sarkar, F.H.6
-
33
-
-
0033527448
-
The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter
-
Vanden BW, De BK, Boone E, Plaisance S, Haegeman G,. The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J Biol Chem 1999; 274: 32091-32098.
-
(1999)
J Biol Chem
, vol.274
, pp. 32091-32098
-
-
Vanden, B.W.1
De, B.K.2
Boone, E.3
Plaisance, S.4
Haegeman, G.5
-
34
-
-
0025720735
-
The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation
-
Angel P, Karin M,. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129-157.
-
(1991)
Biochim Biophys Acta
, vol.1072
, pp. 129-157
-
-
Angel, P.1
Karin, M.2
-
35
-
-
16344365813
-
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 9480
-
George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW,. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 9480. Clin Cancer Res 2005; 11: 1815-1820.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 1815-1820
-
-
George, D.J.1
Halabi, S.2
Shepard, T.F.3
Sanford, B.4
Vogelzang, N.J.5
Small, E.J.6
Kantoff, P.W.7
-
36
-
-
35948969806
-
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
-
Morris MJ, Kelly WK, Slovin S, Ryan C, Eicher C, Heller G, Scher HI,. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. J Urol 2007; 178: 2378-2383.
-
(2007)
J Urol
, vol.178
, pp. 2378-2383
-
-
Morris, M.J.1
Kelly, W.K.2
Slovin, S.3
Ryan, C.4
Eicher, C.5
Heller, G.6
Scher, H.I.7
-
37
-
-
77953091816
-
Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer
-
Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN Jr, Van VP Jr, Quinn DI, Vogelzang NJ, Thompson IM Jr, Hussain MH,. Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 2010; 16: 3028-3034.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3028-3034
-
-
Dorff, T.B.1
Goldman, B.2
Pinski, J.K.3
MacK, P.C.4
Lara, Jr.P.N.5
Van, Jr.V.P.6
Quinn, D.I.7
Vogelzang, N.J.8
Thompson, Jr.I.M.9
Hussain, M.H.10
|